Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P120019/S045

Roche cobas EGFR Mutation Test, v2.0

Roche · Decision date Nov 4, 2026

MEDTECHLEDGER EXPLANATIONP120019/S045

What did the FDA approve?

FDA recorded an approval decision on 2026-11-04 for P120019/S045, a Special (Immediate Track) PMA supplement from Roche. The supplement covers updates to hazard information in the product labeling for the cobas® DNA Sample Preparation Kit, which the source describes as a component of the cobas® KRAS Mutation Test, cobas® BRAF V600 Mutation Test, and cobas® EGFR Mutation Test, v2.0. The supplement reason is listed as a labeling change covering indications, instructions, shelf life or tradename.

This action concerns labeling content for a shared sample-preparation component rather than a new approval of the broader test system; the source does not specify which hazard statements changed or which of the named tests the revised labeling affects. The device category is a somatic gene mutation detection system, specialty pathology, product code OWD. No supporting documents were included, so the revised label text and any clinical implications remain unknown from this record.

Readers should treat the decision as a labeling update only. The source gives no data on analytical or clinical performance, and no conclusion about test use or patient management follows from it.

FDA approval order statement

Approval for updates to the hazard information on the product labeling for cobas DNA Sample Preparation Kit, a component of cobas KRAS Mutation Test, cobas BRAF V600 Mutation Test, and cobas EFGR Mutation Test, v2.0.
Regulatory pathway
PMA supplement
Supplement type
Special (Immediate Track)
Clinical specialty
Pathology
Decision date
Nov 4, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P120019/S045
Regulatory pathway
PMA supplement
Applicant
Roche
Product code
OWD
Decision code
APPR
Decision date
Nov 4, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Somatic gene mutation detection system.

Applicant
Roche
Product code
OWD
FDA device class
3

For the original device and its historical approval scope, see PMA P120019. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P120019 · Original PMA

    COBAS EGFR MUTATION TEST

  2. P120019/S045 received

    Application receipt date recorded by FDA.

  3. P120019/S044 · Related supplement

    cobas EGFR Mutation Test, v2.0

  4. P120019/S045 · FDA decision

    Special (Immediate Track)

Timeline entries are records held by MedtechLedger for P120019. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P120019

Product / regulatory recordCompanyPathwayDecision dateSource
RochePMA approvalMay 14, 2013FDA
RochePMA supplementOct 27, 2026FDA

Explore the linked device profile

Other records with product code OWD

Product / regulatory recordCompanyPathwayDecision dateSource
Roche Molecular Systems, Inc.PMA supplementNov 4, 2026FDA
Roche Molecular Systems, Inc.PMA supplementNov 4, 2026FDA
Roche Molecular Systems, Inc.PMA supplementOct 27, 2026FDA
Roche Molecular Systems, Inc.PMA supplementOct 27, 2026FDA
Roche Molecular System, Inc.PMA supplementOct 27, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Roche

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
4300 Hacienda Dr., P.O. Box 9002, Peasanton, CA, 94588

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records